Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 214


Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.

Orkin C, Llibre JM, Gallien S, Antinori A, Behrens G, Carr A.

HIV Med. 2017 Jul 24. doi: 10.1111/hiv.12534. [Epub ahead of print] Review.


Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: a retrospective analysis of sexual health screening in East London.

Pasvol TJ, Orkin C.

Sex Transm Infect. 2017 Aug;93(5):326. doi: 10.1136/sextrans-2016-053055. Epub 2017 Jul 20. No abstract available.


Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A, Post FA, Sabin C, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

Lancet HIV. 2017 Jul;4(7):e295-e302. doi: 10.1016/S2352-3018(17)30053-X. Epub 2017 May 4.


A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN, Cooper C, Hill T, Hull M, Klein MB, Loutfy M, Martin F, Machouf N, Montaner J, Nelson M, Raboud J, Rourke SB, Tsoukas C, Hogg RS, Sabin C; Canadian Observational Cohort (CANOC) - UK Collaborative HIV Cohort (UK CHIC) Collaboration.

HIV Med. 2017 Apr 24. doi: 10.1111/hiv.12505. [Epub ahead of print]


Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholc L, Kyselyova G, Lundgren JD, Mocroft A; for EuroSIDA.

Clin Infect Dis. 2017 May 15;64(10):1413-1421. doi: 10.1093/cid/cix167.


Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):226-231. doi: 10.1097/QAI.0000000000001344.


Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H.

Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.


HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.


Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.

Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ, Wilkins E, Sanders K, Paton NI; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team.

AIDS. 2016 Nov 13;30(17):2617-2624.


No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn DT; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.

J Infect Dis. 2016 Nov 1;214(9):1302-1308. Epub 2016 May 24.


British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.

Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, Marshall N, Monteiro F, Nelson M, Orkin C, Palfreeman A, Pett S, Phillips A, Post F, Pozniak A, Reeves I, Sabin C, Trevelion R, Walsh J, Wilkins E, Williams I, Winston A.

HIV Med. 2016 Aug;17 Suppl 4:s2-s104. doi: 10.1111/hiv.12426. No abstract available.


Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A, Churchill D, Geretti AM, Pillay D, Sabin C, Leigh-Brown A, Smit E; UK HIV Drug Resistance Database.

HIV Med. 2017 Mar;18(3):204-213. doi: 10.1111/hiv.12414. Epub 2016 Aug 1.


Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women?

Orkin C, Jeffery-Smith A, Foster GR, Tong CY.

BMJ Open. 2016 May 26;6(5):e010661. doi: 10.1136/bmjopen-2015-010661.


Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI; PIVOT Neurocognitive sub-study Team.

Clin Infect Dis. 2016 Jul 15;63(2):257-64. doi: 10.1093/cid/ciw279. Epub 2016 May 3.


Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign.

Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K, Anderson J, Tong CY, Lattimore S.

HIV Med. 2016 Mar;17(3):222-30. doi: 10.1111/hiv.12364.


Infection-related and -unrelated malignancies, HIV and the aging population.

Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2016 Sep;17(8):590-600. doi: 10.1111/hiv.12359. Epub 2016 Feb 18.


Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.

Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T, Khatib N, Das P, Naftalin C, Mackie N, Kingdon E, Williams D, Hendry BM, Sabin C, Jones R, Levy J, Hilton R, Connolly J, Post FA; HIV/CKD Study and the UK CHIC Study.

Nephrol Dial Transplant. 2016 Dec;31(12):2099-2107. Epub 2016 Jan 18.


Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.


TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late diagnosis.

Bath R, O'Connell R, Lascar M, Ferrand R, Strachan S, Matin N, Bassnet I, Orkin C.

AIDS Care. 2016;28(5):608-11. doi: 10.1080/09540121.2015.1120855. Epub 2015 Dec 23.


Should HIV testing week be blood-borne-virus testing week?

Orkin C, Wallis E.

Lancet HIV. 2015 Dec;2(12):e510-1. doi: 10.1016/S2352-3018(15)00227-1. Epub 2015 Nov 16. No abstract available.


Supplemental Content

Loading ...
Support Center